Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Pfizer Team Up on Protein Biomarker Discovery Project

NEW YORK, Oct. 8 — Ciphergen Biosystems and Pfizer said on Monday that they would collaborate on a predictive toxicology study using Ciphergen’s ProteinChip system and arrays. The study will aim to discover proteins in serum from rat models and to evaluate the relative importance and utility of such proteins as biomarkers associated with drug safety. Financial and other terms of the agreement were not disclosed. 

William Rich, president and CEO of Ciphergen, said that, if successful, he expects the collaboration to be expanded into a larger program. The work with Pfizer will be carried out in Ciphergen’s Biomarker Centers in California, Pennsylvania, and Denmark. 

The ProteinChip system enables users to rapidly identify in animal and cell culture models multiple protein biomarkers and biomarker patterns that would be predictive of likely toxicity problems. Among Ciphergen’s existing ProteinChip customers are AstraZeneca, BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, and Pharmacia. 

 

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.